Diese Website verwendet Cookies, damit wir dir die bestmögliche Benutzererfahrung bieten können. Cookie-Informationen werden in deinem Browser gespeichert und führen Funktionen aus, wie das Wiedererkennen von dir, wenn du auf unsere Website zurückkehrst, und hilft unserem Team zu verstehen, welche Abschnitte der Website für dich am interessantesten und nützlichsten sind.
Alverno will deploy Ibex’s AI-powered Galen™ platform, supporting pathologists in improving the quality of cancer diagnosis
Hammond, Indiana, and Tel Aviv, Israel, August 11, 2021 – Alverno Laboratories, a provider of high-quality diagnostic testing services and one of the largest integrated laboratory networks in the United States, and Ibex Medical Analytics, the market leader in artificial intelligence (AI)-powered cancer diagnostics, today announced a deal to deploy Ibex’s AI-powered Galen™ platform, helping pathologists provide accurate diagnosis and improved care for cancer patients.
Pathologists play a crucial role in the detection and diagnosis of disease, with their assessments vital in reaching correct treatment decisions by oncologists. However, a rise in cancer prevalence and advances in personalized medicine have resulted in growing diagnostic complexity that significantly increases pathologists’ workloads. In recent years, as pathology labs transition towards digital solutions, laboratories can implement AI enhanced workflows to improve the quality and efficiency of cancer diagnosis, resulting in better patient care.
Ibex transforms cancer diagnosis by harnessing Strong AI and machine learning technology at an unprecedented scale. Ibex’s Galen platform helps pathologists improve the quality of cancer diagnosis, implement real-time quality control1, reduce diagnosis time and boost productivity2. The platform was recently granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) and is CE marked in Europe for breast and prostate cancer detection in multiple workflows. Galen has already demonstrated outstanding outcomes in clinical studies3,4, and has been deployed in labs worldwide where it is used as part of everyday clinical practice.
Alverno is one of the largest pathology laboratories in the Midwest, managing 32 hospital laboratories, and providing laboratory services to thousands of physician offices. It consults on 150,000 histological cases each year, which translates to more than 1,100,000 slides of human tissue. Alverno is among the first labs in the U.S. to implement digital pathology technologies to ease collaboration across sites and help reduce turnaround times, by deploying Philips’ IntelliSite Pathology Solution as part of its routine workflow. By adding Ibex’s Galen platform, pathologists at Alverno will benefit from clinical-grade AI insights available on different workflows and multiple types of tissue.
“Adopting Ibex’s artificial intelligence solutions and embedding them into our diagnostic pathway would help pathologists, whose numbers are decreasing nationwide leading to an increased workload, focus on more complicated cancer diagnoses that need a trained eye”, said Sam Terese, Alverno CEO. “AI is an ideal “digital assistant” supporting pathologists diagnosing routine cases, and this AI deployment is part of our continued journey to find the most innovative products that make our patients healthier and enhance how our medical professionals work.”
“We are thrilled to team up with Alverno and enable their pathologists to use state-of-the-art AI solutions to accurately detect cancer and improve quality and efficiency of diagnosis,” said Joel Duckworth, Chief Revenue Officer for the Americas at Ibex. “With this roll out, Alverno is setting a new standard in cancer care quality, further proving its leadership and commitment to its patients by deploying an advanced clinical-grade AI solution to ensure the best possible outcomes. Artificial intelligence and digital pathology technologies have become an essential part of cancer care programs, and their adoption is a vision shared by both Alverno and Ibex.”Back